Shire PLC (ADR) (SHPG) reported quarterly earnings results on Friday, Apr-29-2016. The company said it had a profit of $2.12 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $1.11. Analysts had a consensus of $1.01. The company posted revenue of $1709.00 million in the period, compared to analysts expectations of $1699.64 million. The company’s revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.08 EPS.
Many Wall Street Analysts have commented on Shire PLC (ADR). Shire PLC (ADR) was Initiated by Cantor Fitzgerald to “Buy” on Feb 26, 2016. Shire PLC (ADR) was Initiated by Guggenheim to “Neutral” on Feb 10, 2016.
Shire PLC (ADR) closed down -2.05 points or -1.12% at $181.51 with 13,54,588 shares getting traded on Wednesday. Post opening the session at $182.3, the shares hit an intraday low of $180.4 and an intraday high of $183.24 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Shire plc is a biopharmaceutical company. The Company along with its subsidiaries is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience Gastrointestinal (GI) Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate) ADDERALL XR (mixed salts of a single-entity amphetamine) INTUNIV (extended release guanfacine) EQUASYM (methylphenidate hydrochloride) modified release (XL) BUCCOLAM LIALDA (mesalamine)/ MEZAVANT(mesalazine) PENTASA (mesalamine) RESOLOR (prucalopride) REPLAGAL (agalsidase alfa) VPRIV (velaglucerase alfa) FIRAZYR (icatibant) CINRYZE C1 esterase inhibitor (human) FOSRENOL (lanthanum carbonate) XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).